Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

References

• Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther. 2011;13(Suppl 1):S53−S64.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014;16:483−491.
   PubMed Web of Science ®Google Scholar
• Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc. 2009;109:26−36.
   PubMedGoogle Scholar
• Home PD. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab. 2015;17(11):1011−1020.
   PubMed Web of Science ®Google Scholar
• Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract. 2010;64(12):1705–1711.
   PubMed Web of Science ®Google Scholar
• Baynest HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab. 2015;6:541.
   Web of Science ®Google Scholar
• American Society of Hospital Pharmacists. Introduction to pharmacokinetics and pharmacodynamics. [cited 2017 Oct 30]. Available from: https://www.ashp.org/-/media/store%20files/p2418-sample-chapter-1.pdf
   Google Scholar
• Swinnen SGHA, Holleman F, De Vries JH. The interpretation of glucose clamp studies of long-acting basal insulin analogues: from physiology to marketing and back. Diabetologia. 2008;51:1790−1795.
   PubMed Web of Science ®Google Scholar
• Heise T, Ziljstra E, Nosek L, et al. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016;18(10):962−972.
   PubMed Web of Science ®Google Scholar
• Goldman J, Kapitza C, Pettus J, et al. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Curr Med Res Opin. 2017;23:1−11.
   Google Scholar
• Krentz AJ, Heinemann L, Hompesch M. Methods for quantifying insulin sensitivity and determining insulin time-action profiles. In: Krentz AJ, Heinemann L, Hompesch M, editors. Translational research methods for diabetes, obesity and cardiometabolic drug development: a focus on early phase clinical studies. London: Springer-Verlag; 2015. p. 3−43.
   Google Scholar
• Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447−2452.
   PubMed Web of Science ®Google Scholar
• Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19(1):3−12.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Toujeo: EPAR − Product Information. Annex I − Summary of product characteristics. [cited 2018 Apr 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf
   Google Scholar
• Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care. 2015;38(4):637−643.
   PubMed Web of Science ®Google Scholar
• Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787−800.
   PubMed Web of Science ®Google Scholar
• Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamics profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33:515−521.
   PubMed Web of Science ®Google Scholar
• Heise T, Nørskov M, Nosek L, et al. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032−1039.
   PubMed Web of Science ®Google Scholar
• Bailey TS, Pettus B, Roussel R, et al. Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes. Diabetes Metab. 2018;44(1):15−21.
   PubMed Web of Science ®Google Scholar
• Bode BW, Chaykin LB, Sussman AM, et al. Efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (Begin: compare). Endocr Pract. 2014;20:78−91.
   Web of Science ®Google Scholar
• Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859−864.
   PubMed Web of Science ®Google Scholar
• Owens DR. Pharmacokinetics and pharmadynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opin Drug Metab Toxicol. 2016;12:977−987.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254−260.
   PubMed Web of Science ®Google Scholar
• Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17(3):261−7.
   PubMed Web of Science ®Google Scholar
• Porcellati F, Lucidi P, Candeloro P, et al. Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U-300 and glargine U-100 at steady state with individualized doses in type 1 diabetes. Diabetes Care. 2018 Oct 10. pii: dc 180706. [Epub ahead of print]. DOI: 10.2337/dc18-0706
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755−2762.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235−3243.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with insulin glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized, controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386−394.
   PubMed Web of Science ®Google Scholar
• Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217−2225.
   PubMed Web of Science ®Google Scholar
• Matsuhisa M, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016;18(4):375−383.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Yki-Järvinen H, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015;17:835−842.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal R, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihypoglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17:1142−1149.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes Metab. 2017;43:351−358.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859−867.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Giaccari A, et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20(3):541−8.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S1−S153.
   PubMed Web of Science ®Google Scholar
• Heise T, Hövelmann U, Nosek L, et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11(8):1193−1201.
   PubMed Web of Science ®Google Scholar
• Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464−2471.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536−2542.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858−864.
   PubMed Web of Science ®Google Scholar
• Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175−184.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Sawa J, Sakuma N, et al. Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: a randomized, open-label, cross-over study using continuous glucose monitoring profiles. J Diabetes Investig. 2018 Jun 26. Epub ahead of print. DOI:10.1111/jdi.12884
   Web of Science ®Google Scholar
• Yamabe M, Kuroda M, Hirosawa Y, et al. Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: a randomized cross-over study. J Diabetes Investig. 2018 Jul 10 Epub ahead of print. DOI:10.1111/jdi.12894
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Bailey TS, Roussel R, et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab. 2018;20(9):2148−2158.
   PubMed Web of Science ®Google Scholar
• Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on Hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318(1):33–44.
   PubMed Web of Science ®Google Scholar
• Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45−56.
   PubMed Web of Science ®Google Scholar
• Marso SP, McGuire DK, Zinman B, et al. DEVOTE study group. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723−732.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/ml versus insulin degludec 100 units/ml in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147−2154.
   PubMed Web of Science ®Google Scholar
• Zhou FL, Ye F, Gupta V, et al. Older adults with type 2 diabetes (T2D) experience less hypoglycemia when switching to insulin glargine 300 U/mL (Gla-300) vs other basal insulins (DELIVER 3 study). Poster 986-P, the presented at American Diabetes Association (ADA) 77th Scientific Sessions; 2017 Jun 10; San Diego (CA).
   Google Scholar
• Oster G, Sullivan SD, Dalal MR, et al. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. Postgrad Med. 2016;128(8):731−739.
   PubMed Web of Science ®Google Scholar
• Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2014;20(1):75−83.
   PubMed Web of Science ®Google Scholar
• Toujeo Prescribing Information. [cited 2018 Apr 27]. Available from: http://products.sanofi.us/toujeo/toujeo.pdf
   Google Scholar
• Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016;18(4):252−257.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Jinnouchi H, Kaku K, et al. Efficacy and safety of once‐daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26‐week, treat‐to‐target trial. J Diabetes Investig. 2016;7(5):711−717.
   PubMed Web of Science ®Google Scholar
• Tresiba Prescribing Information. [cited 2017 Dec 15]. Available from: http://www.novo-pi.com/tresiba.pdf
   Google Scholar